- Home
- PNRG vs PBYI Comparison
PNRG vs PBYI Comparison
Compare PNRG & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNRG | PBYI |
|---|---|---|
| Founded | 1973 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.3M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PNRG | PBYI |
|---|---|---|
| Price | $183.11 | $5.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 49.4K | ★ 642.3K |
| Earning Date | 11-19-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | ★ 10.31 | 0.74 |
| Revenue | $196,237,000.00 | ★ $211,995,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.43 | ★ $7.12 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $126.40 | $2.58 |
| 52 Week High | $243.49 | $6.12 |
Technical Indicators
Market Signals| Indicator | PNRG | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 71.01 | 54.54 |
| Support Level | $166.41 | $4.84 |
| Resistance Level | $198.63 | $5.11 |
| Average True Range (ATR) | 9.80 | 0.19 |
| MACD | 3.93 | 0.04 |
| Stochastic Oscillator | 83.22 | 83.18 |
Price Performance
Historical ComparisonAbout PNRG PrimeEnergy Resources Corporation
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.